EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY 4.0

Associations of proton pump inhibitors with susceptibility to influenza, pneumonia, and COVID-19: Evidence from a large population-based cohort study

Ruijie Zeng, Yuying Ma, Lijun Zhang, Dongling Luo, Rui Jiang, Huihuan Wu, Zewei Zhuo, Qi Yang, Jingwei Li, Felix W Leung, Chongyang Duan, Weihong Sha und 1 weitere

eLife · 16.07.2024 · 13

DOI: 10.7554/elife.94973 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift eLife, online erschienen am 16.07.2024. Verfasst von Ruijie Zeng und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzho…. Hauptthemen laut MEDLINE: Proton Pump Inhibitors, Influenza, Human, COVID-19, Pneumonia. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Program for High-level Foreign Expert Introduction of China, Natural Science Foundation for Distinguished Young Scholar of Guangdong Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Adverse effects of proton pump inhibitors (PPIs) have raised wide concerns. The association of PPIs with influenza is unexplored, while that with pneumonia or COVID-19 remains controversial. Our study aims to evaluate whether PPI use increases the risks of these respiratory infections.

Methods

The current study included 160,923 eligible participants at baseline who completed questionnaires on medication use, which included PPI or histamine-2 receptor antagonist (H2RA), from the UK Biobank. Cox proportional hazards regression and propensity score-matching analyses were used to estimate the hazard ratios (HRs) and 95% confidence intervals (CIs).

Results

Comparisons with H2RA users were tested. PPI use was associated with increased risks of developing influenza (HR 1.32, 95% CI 1.12–1.56) and pneumonia (hazard ratio [HR] 1.42, 95% confidence interval [CI] 1.26–1.59). In contrast, the risk of COVID-19 infection was not significant with regular PPI use (HR 1.08, 95% CI 0.99–1.17), while the risks of severe COVID-19 (HR 1.19. 95% CI 1.11–1.27) and mortality (HR 1.37. 95% CI 1.29–1.46) were increased. However, when compared with H2RA users, PPI users were associated with a higher risk of influenza (HR 1.74, 95% CI 1.19–2.54), but the risks with pneumonia or COVID-19-related outcomes were not evident.

Conclusions

PPI users are associated with increased risks of influenza, pneumonia, as well as COVID-19 severity and mortality compared to non-users, while the effects on pneumonia or COVID-19-related outcomes under PPI use were attenuated when compared to the use of H2RAs. Appropriate use of PPIs based on comprehensive evaluation is required. Funding: This work is supported by the National Natural Science Foundation of China (82171698, 82170561, 81300279, 81741067, 82100238), the Program for High-level Foreign Expert Introduction of China (G2022030047L), the Natural Science Foundation for Distinguished Young Scholars of Guangdong Province (2021B1515020003), the Guangdong Basic and Applied Basic Research Foundation (2022A1515012081), the Foreign Distinguished Teacher Program of Guangdong Science and Technology Department (KD0120220129), the Climbing Program of Introduced Talents and High-level Hospital Construction Project of Guangdong Provincial People’s Hospital (DFJH201923, DFJH201803, KJ012019099, KJ012021143, KY012021183), and in part by VA Clinical Merit and ASGE clinical research funds (FWL).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Proton Pump InhibitorsInfluenza, HumanCOVID-19PneumoniaHumansMaleFemaleMiddle AgedAgedCohort StudiesHistamine H2 AntagonistsSARS-CoV-2AdultUnited KingdomDisease SusceptibilityProportional Hazards Models

Stichwörter der Autor:innen

COVID-19Proton pump inhibitormedicinenonerespiratory infection

Substanzen

Proton Pump InhibitorsHistamine H2 Antagonists

Autor:innen und Institutionen

  • Department of Gastroenterology, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China.
  • The Second School of Clinical Medicine, Southern Medical University, Guangzhou, China.
  • Shantou University Medical College, Guangdong, China.
  • School of Medicine, South China University of Technology, Guangzhou, China.
  • Guangdong Cardiovascular Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China.
  • David Geffen School of Medicine, University of California Los Angeles, Los Angeles, United States.

ORCID-Profile: Hao Chen

Förderung

  • National Natural Science Foundation of China
  • Program for High-level Foreign Expert Introduction of China
  • Natural Science Foundation for Distinguished Young Scholar of Guangdong Province
  • Guangdong Basic and Applied Basic Research Foundation
  • Foreign Distinguished Teacher Program of Guangdong Science and Technology Department
  • Climbing Program of Introduced Talents and High-level Hospital Construction Project of Guangdong Provincial People's Hospital
  • American Society for Gastrointestinal Endoscopy
  • National Natural Science Foundation of China Regional Innovation and Development Joint Foundation

Zitieren

APA

Zeng, R., Ma, Y., Zhang, L., Luo, D., Jiang, R., Wu, H., Zhuo, Z., Yang, Q., Li, J., Leung, F. W., Duan, C., Sha, W., & Chen, H. (2024). Associations of proton pump inhibitors with susceptibility to influenza, pneumonia, and COVID-19: Evidence from a large population-based cohort study. eLife, 13. https://doi.org/10.7554/elife.94973

Vancouver

Zeng R, Ma Y, Zhang L, Luo D, Jiang R, Wu H, et al. Associations of proton pump inhibitors with susceptibility to influenza, pneumonia, and COVID-19: Evidence from a large population-based cohort study. eLife. 2024;13. doi:10.7554/elife.94973

BibTeX
@article{Zeng2024,
  author = {Zeng, Ruijie and Ma, Yuying and Zhang, Lijun and Luo, Dongling and Jiang, Rui and Wu, Huihuan and Zhuo, Zewei and Yang, Qi and Li, Jingwei and Leung, Felix W and Duan, Chongyang and Sha, Weihong and Chen, Hao},
  title = {Associations of proton pump inhibitors with susceptibility to influenza, pneumonia, and COVID-19: Evidence from a large population-based cohort study},
  journal = {eLife},
  year = {2024},
  volume = {13},
  doi = {10.7554/elife.94973}
}
Kostenlos starten →